The import of penicillins or streptomycins not in dosage forms to the US is forecasted to decline progressively over the next five years. In 2024, the imports are anticipated to be valued at $5.9675 million, decreasing annually to $4.4638 million by 2028. An examination of trends indicates a consistent year-on-year decline, with decreasing values correlating to a trend of diminishing demand or altered supply chain dynamics from global suppliers.
Future trends to watch for:
- Potential shifts in global manufacturing that could impact supply.
- Regulatory changes that may affect import patterns and costs.
- Innovations in antibiotic alternatives that could further alter demand.
